Cyteir Therapeutics, Inc. (CYTT)
- Previous Close
3.0200 - Open
2.9700 - Bid --
- Ask --
- Day's Range
2.9200 - 3.1900 - 52 Week Range
1.6700 - 3.1900 - Volume
458,124 - Avg. Volume
115,950 - Market Cap (intraday)
108.354M - Beta (5Y Monthly) 0.10
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.
cyteir.comRecent News: CYTT
Performance Overview: CYTT
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYTT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYTT
Valuation Measures
Market Cap
108.35M
Enterprise Value
-20.87M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.87
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.50%
Return on Equity (ttm)
-23.80%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-33.22M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
129.24M
Total Debt/Equity (mrq)
0.01%
Levered Free Cash Flow (ttm)
-14.3M
Research Analysis: CYTT
Company Insights: CYTT
CYTT does not have Company Insights